All recalled products have a label that includes the pharmacy name and the name of the compounded drug product. Michelle Cuccia recognized during HBA Rising Star luncheonOn May 14, Teva’s own Michelle Cuccia, Marketing Vice President – Growth Markets, was honored at the annual Healthcare Businesswomen’s Association (HBA) Woman of the Year luncheon. Blood 122(21), 11/2013. 35. Oran B, Quing C, Brunstein C, Majhail N, Weisdorf D. Similar And Promising Outcomes In Older AML Patients In First Complete Remission After Reduced Intensity Conditioning With Cord Blood And Sibling Donor Transplantation. Edinburgh: Churchill Livingstone. p. 3. ISBN 0-443-06527-6. ^ Schmit-Neuerburg, Klaus-Peter; Reiner Labitzke (2000). Manual of Cable Osteosyntheses: History, Technical Basis, Biomechanics of the Tension Band Principle, and Instructions for Operation. The dosing and treatment schedules for Kadcyla and Herceptin, another breast cancer drug, are quite different, so confusion between these products could lead to dosing errors and potential harm to patients.The FDA-approved nonproprietary name for Kadcyla, ado-trastuzumab emtansine, should be used.
Curr Opin Hematol 18(6):395-400, 11/2011. NIHMSID: NIHMS348482. 5. Oran B, de Lima M. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Patients are at increased risk for infections in the event a sterile product is compromised. Health care professionals should follow the new dosing recommendations when starting patients on Lunesta. This request is the result of our ongoing evaluation of infrequent but continuing reports of infections resulting from antiseptic products labeled for preoperative or preinjection skin preparation.
Treatment duration should be limited to 30 days or less, and use should be avoided in patients with underlying liver disease, including cirrhosis. Both ends of the molecule can be attacked by DNA bases, producing a butylene crosslink between two different bases. The Compounding Shop has informed the FDA that it is recalling sterile products and is in the process of notifying customers.The FDA is basing this warning on a recent inspection of The Compounding Shop. The first list includes customer names and addresses, organized by state.